Mugglehead
Subscribe

Quantum X Labs posts US$254K in third-quarter revenue as loss widens

The continuing-operations loss rose to US$5.879 million, including a US$3.84 million charge from deconsolidating CliniQuantum.

Julian Okafor·
A microwave probe station sits on a table in an electronics testing room.
A microwave probe station in a generic electronics testing room. Illustration: Mugglehead, generated with AI.

Third-quarter revenue fell by more than a third at a quantum software developer as its operating loss nearly quadrupled. Quantum X Labs Inc. NASDAQQXL, the Ramat Gan, Israel, company formerly known as Viewbix, reported on Nov. 18 that revenue fell to US$254,000 from US$401,000 a year earlier.

The net loss from continuing operations rose to US$5.879 million from US$1.148 million for the quarter ended Sept. 30. The income statement lists a US$3.84 million loss from deconsolidating CliniQuantum below operating loss.

Quantum X Labs shares NASDAQQXL closed lower at US$3.21 at 4:00 p.m. EST on Nov. 18. The SEC accepted the quarterly filing at 4:16 p.m. EST, after regular trading ended.

The operating loss widened to US$2.048 million from US$525,000 a year earlier, while the quarterly fall in revenue came to about 37 per cent. For the first nine months of 2026, revenue fell to US$900,000 from US$1.3 million in the same period of 2025.

Traffic Costs Rose as Sales Fell

Traffic acquisition and related costs rose to US$147,000 from US$59,000 in the three months ended Sept. 30. They absorbed about 58 per cent of revenue in the 2026 quarter, up from about 15 per cent in the comparable period.

The nine-month totals show traffic costs rising over the longer period as well. They reached US$413,000 through Sept. 30, 2026, up from US$243,000 a year earlier. Traffic costs represented about 46 per cent of nine-month revenue in 2026 and about 19 per cent in 2025.

General and administrative expenses were the largest operating cost. They reached US$1.102 million for the September 2026 quarter, more than twice the US$435,000 recorded a year earlier. Depreciation and amortization also more than doubled, rising to US$598,000 from US$241,000. The increases in those two expenses accounted for about two-thirds of the growth in the quarterly operating loss.

Research and development cost US$150,000 in the September 2026 quarter, up from US$21,000. Research spending reached US$335,000 through Sept. 30, 2026, compared with US$57,000 a year earlier. Mugglehead has also covered the separate timetables for a first recurring contract and a planned chip beta in the quantum security sector.

Read more: BTQ Technologies targets 2027 chip beta alongside first recurring deal

The Quarterly Loss Grew as the Nine-Month Loss Narrowed

The deconsolidation of CliniQuantum accounted for most of the September 2026 quarter's US$6.001 million loss from continuing operations before taxes. Quantum X Labs also recorded US$73,000 as its share of losses from associates accounted for under the equity method in that quarter.

Net financial expenses fell to US$40,000 in the September 2026 quarter from US$645,000 a year earlier. That US$605,000 reduction offset part of the increase in quarterly operating expenses.

Over the nine months ended Sept. 30, 2026, the loss from continuing operations narrowed to US$4.067 million from US$12.729 million. Net financial expenses through September fell to US$224,000 from US$11.173 million in the 2025 period. That decline was more than four times the increase in operating losses, which rose to US$3.993 million from US$1.603 million.

The 2025 quarter also carried a US$2.805 million loss from discontinued operations. That brought the total company-wide net loss for that period to US$3.953 million, of which US$560,000 was attributable to non-controlling interests. The US$5.879 million net loss for the September 2026 quarter came entirely from continuing operations and was attributable to Quantum X Labs shareholders.

The basic loss from continuing operations for the September 2026 quarter was US$0.28 a share. The year-earlier loss on the same basis was US$0.11 a share. The basic weighted-average share count was about 21.3 million, compared with about 10.5 million a year earlier. The company adjusted the prior-year figures for a reverse stock split.

"Share and per share data in these financial statements for periods preceding the Reverse Stock Split have been retrospectively adjusted," Quantum X Labs said in the footnote to its Nov. 18 income statement.

The per-share comparison moved the other way once discontinued operations were included. The total basic loss per share attributable to Quantum X Labs shareholders narrowed to US$0.28 in the September 2026 quarter from US$0.32 a year earlier. The prior-year figure included US$0.21 per share from discontinued operations.

Quantum X Labs' fiscal year ends Dec. 31, the next reporting cutoff for revenue and expenses. The year-end results will set the 2026 revenue total after nine-month sales of US$900,000 through Sept. 30.

More in Markets & Technology

View all